WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class
therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management
will present at the JMP Securities Life Sciences Conference in New York City on Thursday, June 21, 2017 at 11:00 am ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the
development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug
intended to improve hemodialysis vascular access outcomes. Proteon is evaluating vonapanitase in patients with chronic kidney
disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula. Proteon is also evaluating vonapanitase in a
Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
proteon@tenbridgecommunications.com
